Penumbra, Inc. (NYSE:PEN) Director Sells $13,492.70 in Stock

Penumbra, Inc. (NYSE:PEN) Director Bridget O’rourke sold 65 shares of the firm’s stock in a transaction on Tuesday, October 13th. The stock was sold at an average price of $207.58, for a total value of $13,492.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Bridget O’rourke also recently made the following trade(s):

  • On Monday, September 14th, Bridget O’rourke sold 65 shares of Penumbra stock. The stock was sold at an average price of $200.97, for a total value of $13,063.05.
  • On Thursday, August 13th, Bridget O’rourke sold 65 shares of Penumbra stock. The stock was sold at an average price of $237.16, for a total value of $15,415.40.
  • On Friday, July 17th, Bridget O’rourke sold 46 shares of Penumbra stock. The stock was sold at an average price of $189.23, for a total value of $8,704.58.

Shares of Penumbra stock opened at $214.00 on Friday. The company has a quick ratio of 5.06, a current ratio of 7.42 and a debt-to-equity ratio of 0.04. Penumbra, Inc. has a twelve month low of $121.80 and a twelve month high of $241.81. The business has a 50-day moving average price of $203.07 and a 200 day moving average price of $191.18. The firm has a market cap of $7.73 billion, a PE ratio of 737.96 and a beta of 0.64.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.09. Penumbra had a return on equity of 1.25% and a net margin of 2.02%. The firm had revenue of $105.11 million during the quarter, compared to analyst estimates of $100.75 million. During the same quarter in the previous year, the business earned $0.27 EPS. Penumbra’s revenue for the quarter was down 21.7% compared to the same quarter last year. On average, sell-side analysts expect that Penumbra, Inc. will post -0.24 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Penumbra in the 2nd quarter valued at about $38,000. CSat Investment Advisory L.P. increased its stake in Penumbra by 236.1% during the 2nd quarter. CSat Investment Advisory L.P. now owns 410 shares of the company’s stock worth $73,000 after buying an additional 288 shares in the last quarter. Private Advisor Group LLC purchased a new stake in Penumbra during the 2nd quarter worth approximately $100,000. Parallel Advisors LLC increased its stake in Penumbra by 37.8% during the 2nd quarter. Parallel Advisors LLC now owns 933 shares of the company’s stock worth $166,000 after buying an additional 256 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in Penumbra during the 2nd quarter worth approximately $169,000. Hedge funds and other institutional investors own 84.02% of the company’s stock.

A number of analysts have commented on PEN shares. ValuEngine raised Penumbra from a “hold” rating to a “buy” rating in a research report on Monday, October 12th. BofA Securities cut Penumbra from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 8th. Wells Fargo & Company lifted their price target on Penumbra from $205.00 to $255.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Zacks Investment Research cut Penumbra from a “hold” rating to a “sell” rating in a report on Thursday, September 10th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $253.00 price objective on shares of Penumbra in a report on Wednesday, October 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Penumbra currently has an average rating of “Buy” and an average price target of $227.71.

Penumbra Company Profile

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands.

See Also: What is a Buy-Side Analyst?

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.